Brief: Spectral Medical Announces U.S. FDA Approval Of Tigris Trial Protocol Amendment To Expand Inclusion Criteria
29/11/2021 13:06
Nov 29 (Reuters) - Spectral Medical Inc EDT.TO :
* SPECTRAL MEDICAL ANNOUNCES U.S. FDA APPROVAL OF TIGRIS
TRIAL
PROTOCOL AMENDMENT TO EXPAND INCLUSION CRITERIA
* SPECTRAL MEDICAL ANNOUNCES U.S. FDA APPROVAL OF TIGRIS
TRIAL
PROTOCOL AMENDMENT TO EXPAND INCLUSION CRITERIA
* SPECTRAL MEDICAL INC - FIVE ADDITIONAL CLINICAL SITES NOW
PARTICIPATING WITH 15 TOTAL SITES FULLY ON BOARD
Source text for Eikon: ID:nGNX7Fp9ks
Further company coverage: EDT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%